Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It

Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increased 16.2% year over year, up 14.3% in constant currency.

The company reported adjusted EPS of 3.55 euros per share, or $2.04 per ADS, beating the consensus of $1.63.

Dupixent Drives Double-Digit Growth Amid Vaccine Contraction

Dupixent sales increased by 34.8% to 5.7 billion euros. Vaccine sales decreased by 6.6% to 3.2 billion euros, mainly driven by phasing of influenza and lower Beyfortus U.S. sales.

Influenza and COVID-19 vaccine sales decreased 18.8% to 1.26 billion euros, mainly due to phasing of seasonal deliveries in the Northern Hemisphere.

Beyfortus sales decreased 15.4% to 631 million euros, driven by the U.S. (240 million euros, -39.3%), including a lower central order from the Centers for Disease Control and Prevention.

Leadership Prioritizes R&D

Belén Garijo, CEO, said on Friday, “We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organization is focused on managing Sanofi’s post-Dupixent trajectory over the next decade.”

“Our priority is to protect earnings through Dupixent’s loss of exclusivity. We have already begun taking action to improve R&D productivity. Business development and M&A will be critical to complement this transformation. We remain committed to our long-term capital allocation policy, including our progressive dividend."

Upgraded 2026 Guidance

Sanofi upgraded its 2026 guidance and expects sales to grow by a low-teens percentage at CER compared with its prior expectation of around 10% growth.

Business EPS at CER is expected to grow by a mid-teens percentage.

In an analyst call, CEO Garijo said that beyond 2030, Sanofi expects revenues to be impacted only moderately by Dupixent’s loss of exclusivity.

SNY Stock Price Activity: Sanofi shares are trading higher by 2.93% at $44.40 at the time of publication on Friday, according to Benzinga Pro data.

Image via Shutterstock